Ypsomed Holding (SWX:YPSN) Builds In North Carolina, Is The Stock Still Undervalued?

Ypsomed Holding (SWX:YPSN) has drawn fresh attention after announcing its first US advanced manufacturing facility in Holly Springs, North Carolina, a project tied directly to its self injection systems expansion.

Recent trading has been choppy. The 7 day share price return is down 8.16% and the 30 day move is down 13.45%, even though the year to date share price return is 9.09% and the 5 year total shareholder return is 152.39%. This shows that longer term momentum remains intact as investors react to news like the Holly Springs expansion and reassess both growth potential and execution risk around Ypsomed Holding.

Compare Ypsomed Holding's Holly Springs expansion story with other health-focused manufacturers by scanning our hand picked list of solid balance sheet and fundamentals (194 results) for potential opportunities with similar staying power.

After a sharp pullback against strong multi year returns and a fresh US build out, does Ypsomed Holding still offer a skewed payoff in favour of new buyers or has the easy part of the rerating already passed?

Most Popular Narrative: 8% Undervalued

Ypsomed Holding's most followed valuation narrative points to a fair value of CHF387.83 against a last close of CHF357.80, which puts recent share weakness in a different light for anyone tracking the Holly Springs build out.

The analysts have a consensus price target of CHF387.83 for Ypsomed Holding based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the more bullish reporting a price target of CHF440.0, and the most bearish reporting a price target of just CHF280.0.

See why 5 investors see Ypsomed Holding as 8% undervalued.

Result: Fair Value of CHF387.83 (UNDERVALUED)

Still, the Ypsomed Holding story can break if heavy investment in new plants strains cash flow, or if key GLP 1 and Cagrisema related projects underdeliver.

Find out about the key risks to this Ypsomed Holding narrative.

Next Steps

Mixed sentiment around Ypsomed Holding's valuation and execution risk is clear. Move quickly, review the underlying data, and weigh both sides by checking the 4 key rewards and 1 important warning sign.

Looking for more ideas beyond Ypsomed Holding?

Do not stop with a single story. Use the Simply Wall Street screener to spot fresh ideas that match your risk comfort, income goals, and valuation discipline.

• Target potential mispricings by scanning the 190 high quality undervalued stocks and see which businesses the numbers suggest may be trading below their fundamentals.
• Strengthen your income stream by reviewing the 163 dividend fortresses and focus on companies that pair higher yields with resilient payout histories.
• Dial down risk by checking the 103 resilient stocks with low risk scores and concentrate on businesses flagged for more robust balance sheets and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com